Head and Neck Malignancies
Conditions
Interventions
3:Chemotherapy + intravenous injection of recombinant human vascular endostatin (30mg/ m, d1-7 daily). The needle was injected at 0.5cm subcutaneously at the outer edge of the tumor body, and then the
2:Chemotherapy + recombinant human endostatin was pumped into the group (recombinant human endostatin 30mg/ m, d1-d7). Recombinant human endostatin was added into normal saline and made into 220ml, us
1:Chemotherapy alone group (chemotherapy docetaxel 75 mg/ m,d1, cisplatin 30mg/ m,d1-3)
Sponsors
The Second Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) all patients were diagnosed with head and neck squamous cell carcinoma by head and neck CT examination and histological cytology; 2) male or female, aged > 18 years and 50%; 6) the subjects voluntarily received recombinant human vascular endostatin treatment with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1) patients who participated in other clinical trials within 4 weeks before treatment; 2) those who are not expected to be able to tolerate the test; pregnant and lactating women; 3) patients with psychological diseases cannot cooperate with the study; 4) patients with central nervous system diseases or related medical history (such as primary brain tumors, tumor-related apoplexy, cancerous meningitis, and metastatic tumors not under control); The expected survival time with brain metastasis or advanced disease is less than 3 months; 5) the tumor has obvious local ulceration and bleeding, and there are infected people who are active or cannot be controlled.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS;PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| DCR;ORR;QOL; | — |
Countries
China
Contacts
Public ContactLiu Ping
Outcome results
None listed